Chemical Crystal Movie Gallery
DDI Time Lapse Sequences
Marketed under the trade name Videx, didanosine (DDI) is a nucleotide antagonist originally used in the treatment of HIV/AIDS following AZT administration. Serious side effects associated with use of DDI, however, hamper drug therapy based on this pharmaceutical.
Better known to biochemists as 2',3'-dideoxyinosine or 9-(2,3-didesoxy-beta-para-ribofuranosyl)-1,9-dihydro-6H-purin-6-one, DDI is a synthetic purine nucleoside. It acts as a reverse transcriptase inhibitor, preventing further reproduction, but not affecting existing viruses. Often, didanosine is used in combination with other agents, including a protease inhibitor, to treat infections with the human immunodeficiency virus. Rapidly metabolized in the patient's liver, the half-life of elimination after ingestion is between 1 and 2 hours. Functioning as an antagonist of nucleotides, this organic compound appears to prevent uncontrolled replication of the HIV/AIDS viruses. Doctors often prescribe it to patients with advanced infections who have deteriorated under AZT treatment. An additional effect of DDI treatment is an increase in the number of CD4 helper white blood cells, from the depressed counts associated with advanced stages of this viral scourge. Unfortunately, didanosine often produces serious side effects including pancreas inflammation, painful nerve damage, and occasionally death.
In its pure white crystalline powder form, DDI is composed of 10 carbon, 12 hydrogen, 4 nitrogen, and 3 oxygen atoms, and has a molecular weight of 236.2. An aqueous solution of didanosine has a pH of about 6.0. The therapeutic chemical becomes unstable in more acidic solutions, with 10 percent decomposing to hypoxanthine in less than 2 minutes at pH 3. This partially explains the mechanism by which the active ingredients enter the blood stream through the gastrointestinal lining following ingestion. As the second antiretroviral agent approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV/AIDS, didanosine was labeled in 1991 only for use following prolonged AZT treatments. More recently, the FDA approved DDI as a front-line therapy against the deadly viruses.
DDI Time Lapse Sequence #1 - Beginning with a nearly-dark viewfield showing the isotropic melt in polarized light, this 19-image time-lapse sequence illustrates the progressive crystallization of birefringent lath-shaped crystals radiating from several nucleation sites.
DDI Time Lapse Sequence #2 - Lath-like crystals form in fan-shaped patterns that intersect as crystallization progresses in a time-lapse sequence of 24 images.
DDI Time Lapse Sequence #3 - A time-lapse sequence of 17 images exhibits nearly-uniform blue birefringence across the viewfield as fan-like crystallites merge during their growth.
Omar Alvarado, Thomas J. Fellers and Michael W. Davidson - National High Magnetic Field Laboratory, 1800 East Paul Dirac Dr., The Florida State University, Tallahassee, Florida, 32310.
Questions or comments? Send us an email.
© 1995-2018 by Michael W. Davidson and The Florida State University. All Rights Reserved. No images, graphics, software, scripts, or applets may be reproduced or used in any manner without permission from the copyright holders. Use of this website means you agree to all of the Legal Terms and Conditions set forth by the owners.
This website is maintained by our